NCT01706367View on ClinicalTrials.gov

Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years

PHASE1CompletedINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Clostridium Difficile Associated Disease
Interventions
BIOLOGICAL

C. difficile vaccine

0.5 mL IM injection

BIOLOGICAL

C. difficile vaccine +adjuvant

0.5 mL IM injection

BIOLOGICAL

C. difficile vaccine

0.5 mL IM injection

BIOLOGICAL

C. difficile vaccine +adjuvant

0.5 mL IM injection

BIOLOGICAL

C. difficile vaccine

0.5 mL IM injection

BIOLOGICAL

C. difficile vaccine +adjuvant

0.5 mL IM injection

Trial Locations (4)

27518

Pfizer Investigational Site, Cary

33026

Pfizer Investigational Site, Pembroke Pines

33143

Pfizer Investigational Site, South Miami

66212

Pfizer Investigational Site, Overland Park

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01706367 - Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years | Biotech Hunter | Biotech Hunter